Symrise AG

Definitions. Symrise steers on adjusted ("normalized") EBITDA, adjusted EPS and Business Free Cash Flow (BFCF = operating cash flow less capex, lease payments and similar items). Reported IFRS figures diverge in FY2025 because of €295 m non-cash impairments on terpenes and Swedencare.

Income statement

FY2021–FY2024: Symrise annual reports (AR, to verify). FY2025: Symrise FY2025 results release (4 March 2026). FY2025 reported net income is not stated in the sources retrieved; IFRS EPS of €1.78 implies roughly €250 m on ~140 m shares (derived, not disclosed figure).

Margins and growth

FY2025 reported EBITDA margin and net margin derived from disclosed figures. Revenue CAGR FY2021–FY2025 = (4929/3826)^(1/4) − 1 ≈ 6.5% (derived).

Commentary. FY2022 was the inflection to scale (sales +21%, partly FX and acquisitions) but margin compressed to 19.6% as raw-material and energy inflation outpaced pricing. FY2023 saw reported EBITDA hit by one-offs (portfolio and efficiency costs), with normalized margin recovering to ~20.6%. FY2024 delivered exceptional 10.3% organic growth, much of it price-driven in Pet Nutrition (egg protein) and strong volume recovery. FY2025 is the mirror image: organic growth slowed to 2.8% as pet nutrition prices normalised, and FX/portfolio effects reduced reported revenue by €210 m, yet adjusted EBITDA rose to €1,081 m and margin reached a decade high of 21.9%, helped by €50 m of savings (target €40 m). The key quality issue is the gap between adjusted and reported earnings: €295 m of impairments cut IFRS EPS to €1.78 versus adjusted €3.67.

Balance sheet

FY2025 net debt of €1.62 bn (down €216 m, implying FY2024 €1.836 bn) per FY2025 release coverage; net debt including pension provisions and leases of €2.1 bn at year-end 2025, rising to €2.3 bn at 30 June 2026 (H1 2026 call). Discrepancy note: the two net-debt figures differ by definition, not error.

Cash flow

FY2024/FY2025 dividends paid derived as prior-year DPS × ~140 m shares (FY2023 DPS €1.10; FY2024 DPS €1.20) — derived, verify. The €400 m buyback commenced 1 February 2026 and therefore falls in FY2026. H1 2026 adjusted BFCF was €347 m (13.7% of sales), up 47% year on year.

Ratios

Derived from figures above. H1 2026 net leverage (incl. pensions and leases) was 2.2x, inside the 1.5–2.5x target range.

Trend commentary. Leverage peaked after the ADF/IDF acquisition (2019) and the 2021–22 bolt-ons and has trended down as EBITDA grew and cash conversion improved; the 2026 buyback and Floral Concept acquisition lift absolute net debt modestly but leverage remains within target. Cash conversion is the most important improvement of the Parisot era: working-capital discipline, supplier terms and capex control drove record BFCF in FY2025 and +47% in H1 2026.

Management guidance (FY2026): organic growth 2–4%; adjusted EBITDA margin 21.5–22.5%; adjusted BFCF margin above 14%. Medium term (2025–2028): 5–7% organic CAGR, 21–23% EBITDA margin, BFCF margin above 14%.

Bull case.

1. Organic momentum has turned: Q2 2026 growth of 4.5% versus −0.4% in Q1 suggests the 2026 run-rate exits near the medium-term range, with Food & Beverage and Consumer Fragrance accelerating.

2. Cash and capital return: BFCF rose 47% in H1 2026 and the €400 m buyback plus progressive dividend give a ~4–5% combined yield, while leverage remains within target.

3. Portfolio quality is improving: exiting terpenes (~US$200 m low-margin sales) and adding Floral Concept lifts mix toward higher-margin, premium businesses.

Bear case.

1. Even at 2–4% growth, Symrise is far from its 5–7% CAGR ambition; achieving it implies a sharp acceleration in 2027–28.

2. S&C remains structurally weaker (17.7% margin) and exposed to volatile UV filters and aroma molecules.

3. Repeated impairments raise questions about past M&A discipline, and the stock trades at ~21x forward earnings, a premium to the broader chemicals sector.

Catalysts and monitorables (next 12 months).

• Q3 2026 trading statement (late October 2026): sustaining Q2 momentum.

• Completion of buyback and share cancellation.

• Closing of Floral Concept.

• Q4 disposal loss from AmeriTerpenes and its effect on reported EPS.

• FY2026 results (expected March 2027), 2027 guidance and any capital-allocation update.

• EU antitrust investigation outcome.

• Pet nutrition pricing stabilisation and EAME recovery.

Analyst verdict. Symrise enters late 2026 in better shape than its share price implied at the start of the year. The Parisot era has turned the company's narrative from diversification to discipline: margins are at a decade high, cash conversion is the best in years, management has been willing to admit and write down past mistakes, and for the first time the company is returning surplus capital through buybacks. The second quarter of 2026 delivered the inflection investors had waited for, with organic growth accelerating to 4.5% and Food & Beverage, Consumer Fragrance and Aroma Molecules all contributing. The balance sheet remains comfortably within its leverage target even after the buyback and a premium naturals acquisition.

The unresolved question is growth. The 2025–2028 targets require 5–7% organic growth per year, yet 2025 delivered 2.8% and 2026 is guided at 2–4%. Hitting the midpoint of the medium-term range would require 2027 and 2028 to run materially above anything achieved since the price-led surge of 2024. Pet nutrition pricing has normalised, Europe remains sluggish, and Scent & Care, despite new leadership, still lags Taste, Nutrition & Health by almost seven percentage points of margin.

Our synthesis: Symrise is a high-quality, cash-generative franchise with a defensible pet palatability moat and improving execution, priced at roughly 21x forward earnings — a discount to its own history and to Givaudan, but not distressed. The investment case over the next 12 months rests less on margins, which look secure within the 21.5–22.5% band, than on evidence that organic growth can be sustained at 4% or better. If the Q3 and Q4 2026 prints confirm the Q2 acceleration, the stock has room to re-rate toward the upper end of analyst targets; if growth fades back to low single digits, the medium-term targets will lose credibility and the shares are likely to remain range-bound.